American Capital and Indian Capacity Are Building the Same Medicine Supply

The United States bought $15.06 billion of pharmaceutical products from India in 2025. That makes India the fourth-largest supplier of medicines into the American market, after Ireland at $42.57 billion, Germany at $26.11 billion and Switzerland at $19.44 billion, and ahead of Belgium at $11.97 billion and France at $11.53 billion. Customs records at the ten-digit tariff line are the source; this is measured trade, not an estimate.

The year-on-year move is the part worth sitting with. India supplied $12.47 billion in 2024, so 2025 represents growth of roughly 20.8 percent in a single year. Widen the lens to include the organic chemistry that feeds formulation, and the basket reaches $19.13 billion in 2025 against $10.99 billion in 2020. Through the first five months of 2026, the same basket already stands at $5.86 billion.

What American investors already own

Here is where two separate views of the same economy become one picture. The trade record tells you where medicines are made. Institutional filings tell you who owns the companies selling them. Reading those together is more instructive than reading either alone.

As of 31 March 2026, State Street held $32.75 billion of Eli Lilly, amounting to 1.131 percent of its entire reported portfolio. Fidelity held $16.72 billion of the same company. Lilly carries a market capitalisation of about $951.3 billion on revenue of roughly $79.67 billion. In Pfizer, State Street reported $8.47 billion, Point72 $122.6 million and D.E. Shaw $107.8 million on the same reporting date.

These are index-scale and strategy-scale positions in companies whose products depend on an input chain that runs through Indian plants. An investor holding a percentage point of its book in one American drugmaker has a direct interest in the reliability of suppliers eight thousand miles away. That interest is rarely stated in those terms, and it should be.

The capital is moving in both directions

American exposure to Indian pharmaceutical capability is the better-known half of this relationship. The other half is Indian capital arriving in the United States, and it is larger than most American executives assume.

Indian companies have committed $50.40 billion across 18,661 outbound investment transactions into the United States since 2011, involving 8,608 distinct Indian firms. This is firm-level regulatory data, current to April 2026, not a survey. Since April 2025 alone, financial, insurance and business services attracted $4.75 billion of fresh Indian commitment, and manufacturing a further $1.33 billion.

Eight thousand six hundred Indian companies have opened, bought or funded something in America. That is a constituency, and it is one that American state economic development offices, banks and law firms are only beginning to serve properly.

The composition of that recent commitment is as telling as its size. Financial, insurance and business services took $4.75 billion across 1,443 separate transactions since April 2025, while manufacturing accounted for $1.33 billion across 489. The services number reflects Indian firms building client-facing operations on American soil rather than serving America from a distance. The manufacturing number is smaller but harder won, because each transaction represents a physical facility decision with a multi-year horizon behind it.

Reading the trajectory honestly

A five-year view puts the current moment in proportion. The combined medicines and chemistry basket stood at $10.99 billion in 2020 and reached $19.13 billion in 2025. That is close to a doubling across a period that included a pandemic, a freight-rate spike and a substantial reordering of where American buyers were willing to source from.

One caution on the 2026 figure. The $5.86 billion recorded so far covers January through May only, and recent months in customs data fill in as filings are processed. It is a partial read and should be treated as one. Anybody projecting a full year from five months of a still-settling series is inventing a number rather than reporting one, and I would rather give you the measured position and let you wait for the rest.

What this means for the year ahead

Three things follow for anyone allocating capital or planning a supply strategy.

First, supply concentration is now an investment question rather than a procurement footnote. When a single origin accounts for the fourth-largest share of a category that American patients rely on daily, the institutions holding those equities are underwriting that origin whether or not they have examined it.

Second, the growth rate matters more than the level. A category that expands roughly 20.8 percent in a year is one where relationships, qualification and capacity commitments are being decided right now. Positions taken in 2026 will look obvious in 2029.

Third, the two-way flow changes the conversation. India is not solely a place American companies buy from. It is a place American companies raise capital alongside, and increasingly a source of investment into American plants and services businesses. The corridor has stopped being one-directional, and the commercial architecture around it has not caught up.

Zovora tracks this corridor at the tariff line and at the firm level, joining customs records to listed-company fundamentals and institutional ownership. The numbers in this column come from that combined view. My argument is simply that the two halves belong in the same conversation, and that American boards which read them together will see the corridor before their competitors price it.

James Sterling is Chief Executive Officer of US Operations at Zovora AI Technologies, Inc., based in New York. Figures are drawn from United States customs records at the ten-digit tariff line, Reserve Bank of India outbound investment filings current to April 2026, and institutional holdings reported as of 31 March 2026.